Psoriasis

Psoriasis has long been linked to cardiovascular disease, including coronary artery disease, myocardial infarction, and heart failure.

Dr Mark Lebwohl provides insight into the educational needs of both patients and providers surround the utilization of spesolimab and its importance in the management of patients with generalized pustular psoriasis.

Mark G. Lebwohl, MD, comments on the clinical implications of the recent approval of spesolimab for the treatment of generalized pustular psoriasis.

An expert in dermatology presents the case of a 64-year-old female with a long history of plaque psoriasis, focusing on her disease severity and age-related management considerations.

Expert dermatologists discuss the risk of candidiasis with IL-17 inhibitors when managing plaque psoriasis and how to manage candidiasis.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss the novel mechanism of bimekizumab and how it can change the treatment landscape for plaque psoriasis.

Goals of generalized pustular psoriasis treatment are reviewed by Dr Mark Lebwohl, where he comments on the need to consider patient disease severity and comorbidities.

Dr Mark Lebwohl comments on the treatment and management considerations for a patient suffering from severe generalized pustular psoriasis, highlighting the inefficiency of systemic steroids in the management of this condition.

Mark G. Lebwohl, MD, introduces the case of a 28-year-old female nurse with a long history of psoriasis, commenting on her past medical history and initial presentation.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.

Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.

Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss how to select treatment for plaque psoriasis based on mechanism of action.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss pathogenesis of plaque psoriasis and new emerging targets.

At the 2022 Fall Clinical Dermatology Conference, Bruce E. Strober, MD, PhD, reviewed the best treatment options for patients with psoriasis and psoriatic arthritis.

At the 2022 Fall Clinical Dermatology Conference, 5 practitioners share their best tips for treating their patients

At the 2022 Fall Clinical Dermatology Conference in Las Vegas, Aaron S. Farberg, MD, shares data on the treatment of plaque psoriasis using tildrakizumab-asmn.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide impressions to the case and take-home messages for dermatologists and rheumatologists treating psoriasis.

Mark G. Lebwohl, MD, presents a case of a 45-year-old Caucasian male diagnosed with psoriasis.

Continued research and development are resulting in exciting new treatment options for major dermatological conditions.

Drs Mark G. Lebwohl and Joseph F. Merola discuss the use of biosimilars in psoriasis and how biosimilars will change the treatment landscape.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide insight on when it is appropriate to switch from one biologic to another for a patient with psoriasis.

Acne, molluscum, atopic dermatitis, and other dermatological disorders can be detrimental to quality of life for children and their families.

Expert dermatologists discuss different anti-TNF molecules and the impact of having these types of molecules on psoriasis and psoriatic arthritis care.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss different head-to-head studies in psoriasis.

Two expert dermatologists discuss the relationship between PsA and PsO in this DermView series recap.

New research finds psoriasis drug apremilast could help patients lose weight.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide tips to overcome diagnostic delay in psoriasis.

Expert dermatologists discuss challenges in diagnosing a patient with PsA.

Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.